- /
- Supported exchanges
- / F
- / HTD.F
Corcept Therapeutics Incorporated (HTD F) stock market data APIs
Corcept Therapeutics Incorporated Financial Data Overview
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Corcept Therapeutics Incorporated data using free add-ons & libraries
Get Corcept Therapeutics Incorporated Fundamental Data
Corcept Therapeutics Incorporated Fundamental data includes:
- Net Revenue: 964 M
- EBITDA: 113 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Corcept Therapeutics Incorporated Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-11-03
- EPS/Forecast: 0.84
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Corcept Therapeutics Incorporated News
New
Corcept Therapeutics (CORT) Faces A Valuation Test As Profit Jumps And Pipeline Hopes Build
Corcept Therapeutics (CORT) just delivered a sharp jump in profitability in its third quarter report, with net income of US$126.78 million and diluted EPS of US$1.01 from continuing operations. That ...
Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64% as ...
This article first appeared on GuruFocus. Total Revenue: $340.5 million in Q3 2026, up 33% QoQ and 64% YoY. Cushing's Syndrome (Korlym) Revenue: $249.1 million. Lifyorli (Oncology) Revenue: $91.4 mil...
CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y Revenues
Corcept Therapeutics CORT reported third-quarter 2026 earnings of $1.01 per share, which comprehensively beat the Zacks Consensus Estimate of 68 cents. Earnings surged 531.3% year over year from 16 ce...
Corcept Therapeutics falls on guidance despite earnings beat
Investing.com -- Corcept Therapeutics Incorporated (NASDAQ:CORT) reported third-quarter results that exceeded analyst expectations, though shares fell 3.9% in after-hours trading Tuesday as the compan...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.